# Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

> **NCT00156286** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 20 (—)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Gleevec

## Key facts

- **NCT ID:** NCT00156286
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2006-01
- **Final completion:** 2006-04
- **Target enrollment:** 20 (—)
- **Last updated:** 2010-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00156286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00156286, "Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00156286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*